Evidence map›Paper›PMID 39709489›Full record

ArticleMicrobiome2024

Screening and identification of antimicrobial peptides from the gut microbiome of cockroach Blattella germanica.

Sizhe Chen, Huitang Qi, Xingzhuo Zhu, Tianxiang Liu, Yuting Fan, Qi Su, Qiuyu Gong, Cangzhi Jia, Tian Liu

Abstract read
In one paragraph

Article in Microbiome, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 13 papers.

0numbers the graph read from it
0cells of the map it votes in
13citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

13 citing papers in PubMed.

  1. Review
  2. Article
  3. Article
  4. SET-M33 peptide as a selectiveMicrobiology spectrum · 2026
    Article
  5. Genome and Secondary Metabolites Analysis ofJournal of fungi (Basel, Switzerland) · 2026
    Article
  6. Article
  7. Article
  8. Article
  9. Article
  10. Article
  11. Article
  12. Article
  13. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

9 authors.

Sizhe Chen *MOE Key Laboratory of Bio-Intelligent Manufacturing, School of Bioengineering, Dalian University of Technology, Dalian, Liaoning, 116024, China.
Huitang Qi *MOE Key Laboratory of Bio-Intelligent Manufacturing, School of Bioengineering, Dalian University of Technology, Dalian, Liaoning, 116024, China.
Xingzhuo Zhu *Department of Thoracic Surgery, The First Affiliated Hospital of Xiaan Jiaotong University, Xian, 710061, China.
Tianxiang LiuSchool of Science, Dalian Maritime University, Dalian, 116026, China.
Yuting FanMOE Key Laboratory of Bio-Intelligent Manufacturing, School of Bioengineering, Dalian University of Technology, Dalian, Liaoning, 116024, China.
Qi SuMicrobiota I-Center (MagIC), Hong Kong SAR, China.
Qiuyu GongDepartment of Thoracic Surgery, The First Affiliated Hospital of Xiaan Jiaotong University, Xian, 710061, China. gongqiuyu@xjtu.edu.cn.
Cangzhi JiaSchool of Science, Dalian Maritime University, Dalian, 116026, China. cangzhijia@dlmu.edu.cn.
Tian LiuMOE Key Laboratory of Bio-Intelligent Manufacturing, School of Bioengineering, Dalian University of Technology, Dalian, Liaoning, 116024, China. tianliu@dlut.edu.cn.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

backgroundThe overuse of antibiotics has led to lethal multi-antibiotic-resistant microorganisms around the globe, with restricted availability of novel antibiotics. Compared to conventional antibiotics, evolutionarily originated antimicrobial peptides (AMPs) are promising alternatives to address these issues. The gut microbiome of Blattella germanica represents a previously untapped resource of naturally evolving AMPs for developing antimicrobial agents.

resultsUsing the in-house designed tool "AMPidentifier," AMP candidates were mined from the gut microbiome of B. germanica, and their activities were validated both in vitro and in vivo. Among filtered candidates, AMP1, derived from the symbiotic microorganism Blattabacterium cuenoti, demonstrated broad-spectrum antibacterial activity, low cytotoxicity towards mammalian cells, and a lack of hemolytic effects. Mechanistic studies revealed that AMP1 rapidly permeates the bacterial cell and accumulates intracellularly, resulting in a gradual and mild depolarization of the cell membrane during the initial incubation period, suggesting minimal direct impact on membrane integrity. Furthermore, observations from fluorescence microscopy and scanning electron microscopy indicated abnormalities in bacterial binary fission and compromised cell structure. These findings led to the hypothesis that AMP1 may inhibit bacterial cell wall synthesis. Furthermore, AMP1 showed potent antibacterial and wound healing effects in mice, with comparable performances of vancomycin.

conclusionsThis study exemplifies an interdisciplinary approach to screening safe and effective AMPs from natural biological tissues, and our identified AMP 1 holds promising potential for clinical application.

Indexed as

Anti-Bacterial AgentsAntimicrobial PeptidesGastrointestinal MicrobiomeAnimalsBacteriaBlattellidaeCockroachesHumansMiceMicrobial Sensitivity TestsAnti-Bacterial AgentsAntimicrobial PeptidesAntimicrobial peptidesBlattella germanicaDeep learning toolGut microbiomeIn vivo activity

Identifiers

PMID39709489
PMCPMC11663339

What Socratic holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.